Mansi Saxena, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an overview of the development of neoantigen vaccines. Neoantigens, antigens exclusively expressed on tumors, enable immune evasion in tumors. Whilst previous trials assessing neoantigen vaccines have taken place, the Phase I trial (NCT02721043) investigating the PGV_001 neoantigen vaccine will have a broader inclusion criteria. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть